You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 2.5% | 3.6% |
Div Cover | 3.7 | 2.6 |
Op Mrgn | 22.2% | 27.5% |
ROCE | 67.1% |
Latest | Forecast | |
---|---|---|
P/E | 11.0 | 0.0 |
PEG | 1.0 | 6.9 |
Price / Revenue | 2.3 | 2.2 |
Price / Book value | 5.5 |
Latest | Forecast | |
---|---|---|
Revenue | 3.4% | 2.0% |
PBT | 7.7% | n/a |
EPS | 11.0% | 0.9% |
DPS | -4.5% | 1.8% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
2021-12-31 | 24,696.00 | 3,599.00 | 90.56p | 22.2 | -1.0 | -22% | 80.00p | 4.0% |
2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.2 | 54% | 44.00p | 3.1% |
2023-12-31 | 30,328.00 | 6,064.00 | 155.10p | 9.4 | 0.8 | 11% | 42.00p | 2.9% |
GSK unveils promising results from endometrial cancer trial Sharecast News | 18 Mar |
---|---|
GSK reports more encouraging trial results for Blenrep Sharecast News | 07 Mar |
GSK's ViiV upbeat on ultra-long-acting HIV treatment study Sharecast News | 05 Mar |
Director/PDMR Shareholding | 26-Mar-24 15:34 |
---|---|
Notice of AGM | 25-Mar-24 13:04 |
Transfer of Treasury Shares | 22-Mar-24 16:23 |
Director/PDMR Shareholding | 22-Mar-24 15:37 |
New Phase III Jemperli data in endometrial cancer | 18-Mar-24 10:21 |